Cancer Therapies: Market Research Report

Date: October 22, 2011
Pages: 897
Price:
US$ 4,500.00
Publisher: Global Industry Analysts, Inc
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: CEF6D7733DAEN
Leaflet:

Download PDF Leaflet

Cancer Therapies: Market Research Report
This report analyzes the worldwide markets for Cancer Therapies in US$ Million by the following Product Segments: Immunotherapy, Targeted Therapy, Hormonal Therapy, and Chemotherapy.

The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World.

Annual estimates and forecasts are provided for the period 2009 through 2017.

A six-year historic analysis is also provided for these markets.

The report profiles 152 companies including many key and niche players such as Amgen, Inc., AstraZeneca PLC, Bayer Schering Pharma, Biogen Idec Inc., Bristol-Myers Squibb Company, Celgene Corporation, Cell Therapeutics, Inc., Cephalon, Inc., Chugai Pharmaceutical Co., Ltd., Eli Lilly and Company, Imclone Systems, Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., Genzyme, GlaxoSmithKline, Janssen Biotech, Inc., Merck KGaA, Novartis AG, OSI Pharmaceuticals, Inc., Pfizer, Sanofi-Aventis, Seattle Genetics, Inc., and Takeda Pharmaceutical Company Limited.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Immunotherapy
Targeted Therapy
Hormonal Therapy
Chemotherapy

2. INDUSTRY OVERVIEW

Cancer Therapies: An Outlook
US Retains Global Dominance
Immunotherapies Lead the Suite, Targeted Therapies to Claim the Top Spot
Cancer Therapies: A Review
Enduring Success of Top Drug Makers Makes Oncology Area More Endearing

Table 1. Select Leading Cancer Therapies Worldwide by Revenues: 2006-2010 (includes corresponding Graph/Chart)

Monoclonal Antibodies Open Up a New Era in Cancer Treatment

Table 2. Leading Monoclonal Antibodies Worldwide by Revenues: 2009 & 2010

Biotherapies to Drive Growth in Cancer Therapy Market
Biotech Cancer Therapies Yet to Overcome Teething Issues
Oncology Drugs – the Leader in the Global Pharma Pipeline

Table 3. Cancer Therapies Market: Number of Approved/Marketed and Pipeline Drugs by Select Cancer Types as of 2010 (includes corresponding Graph/Chart)

New Cancer Therapies Appear Over the Horizon
Late Stage Promising Drugs in Cancer Therapy
US Ahead in Approving Cancer Drugs
FDA-Approved Oncology Drugs in Recent Years (2008-2011)
New Cancer Drugs Approved by EMA in 2009 and 2010
Competition Set to Rise in Cancer Therapy

Table 4. Leading Companies in the Global Oncology Therapy Market (2010): Percentage Breakdown of Revenues for Roche, Novartis, Amgen, AstraZeneca, sanofi-aventis and Celgene (includes corresponding Graph/Chart)

Competition Intensifies in the Cancer Biotherapy Segment

3. TRENDS AND ISSUES

Innovations in Cancer Drug Delivery: A Key Factor in Product Differentiation
Follow-On Indications Flock Oncology Pipeline
Personalized Medicine: Gain in Importance
Combination Therapy: A Double Whammy Success
Patent Expiries of Branded Drugs to Trigger Generic Competition
Rising Investments Bring in New Troubles for Drug Makers
Emerging Challenges in Cancer Drug Development
Select Drugs Receiving Complete Response Letters from the FDA in 2010
Drug Failures – Deterring Prospects of New Therapies
Failures in Phase III Clinical Trials of Oncology Drugs in 2010
Drug Withdrawals Hurt Pharma Companies

4. MARKET DRIVERS AND RESTRAINTS

Growth Drivers In a Capsule
Rise in Cancer Incidences & Access to Modern Therapeutics Foster Growth
Demographics & Lifestyles Raise the Risk of Cancer
Cancer Prone Sites based on Age

Table 5. Population of People Aged More than 65 Years in United States for the years 2000, 2010, and 2020 (includes corresponding Graph/Chart)

Unmet Needs Leave Scope for Further Research and Development
Low Entry Barriers in Cancer Research Encourages Breakthrough Developments
Increasing Investments by National Health Authorities
Efficiency & High Prices Magnetize Manufacturers
Supportive Cancer Drugs Contribute to Growth
Improved Screening, Diagnosis & Patient Survival Rates Trigger Growth
Molecular Imaging of Cancer: Critical in Improving Patient Outcomes
Innovations, Improvements, and Approvals Propel Growth
Growth Restraints
High Prices of Targeted Therapies Act as a Speed Breaker

Table 6. Estimated Average Monthly Cost of Select Leading Cancer Drugs in the US as of 2008

Limited Tumor Specificity and Toxicity
Complicated Treatment Protocols: A Major Stumbling Block in Patient Compliance
Reduced Smoking
Reimbursement and Coverage Remains a Major Challenge
Changes in Reimbursement Policies Influence Market Prospects
Multiple Drug Resistance
Stringent Regulations Delay Market Approval
Challenges Encountered in Clinical Trials
High Development Costs Retracts Manufacturers in Developing Countries

5. TARGETED THERAPEUTICS

Current and Future Analysis
Targeted Therapy – An Overview
Targeted Therapy: The New Frontier of Cancer Treatment
List of Select Approved Targeted Therapy Drugs by Indication
Select Targeted Anti-Cancer Therapies in Late-Stage (Phase III) Clinical Development

Table 7. Targeted Therapies Market Worldwide (2010): Percentage Breakdown of Targeted Therapeutic Drugs under Various Stages of Development (includes corresponding Graph/Chart)
Table 8. Molecular Targeted Therapies Worldwide: Percentage Breakdown of Molecular Targeted Therapies under Pipeline by Drug Class as of 2010 (includes corresponding Graph/Chart)

Types of Targeted Therapy
Tyrosine Kinase Inhibitors
List of Approved Tyrosine Kinase Inhibitors
Angiogenesis Inhibitors
List of Approved Angiogenesis Inhibitors
Proteasome Inhibitors
Multi-Targeted Drugs
Select Approved Multi-Targeted Drugs in Targeted Cancer Therapy
Gene Therapy

6. IMMUNOTHERAPY

Current and Future Analysis

Table 9. Global Market for Immunotherapy (2007 and 2012): Percentage Breakdown of Revenues by Drug Class – Monoclonal Antibodies, Biological Response Modifiers, Vaccines, and Other Immunotherapy Products (includes corresponding Graph/Chart)

Immunotherapy Treatment Strategies
Vaccination with Dendritic Cells Pulsed With Tumor Antigens
Gene Technique-Based Immunotherapy
Inhibiting Tumor-Induced Immunosuppression
Immunostimulants
Use of Monoclonal Antibodies
Immunotoxins
Radioimmunotherapy
T Cells based Therapy
Types of Cancer Immunotherapy Drugs
Monoclonal Antibodies
Select Immunotherapy-based Monoclonal Antibodies Approved for Cancer Treatment
Vaccines – A Promising Future Area of Cancer Therapeutics
Therapeutic Cancer Vaccines: Harnessing the Immune System to Fight Cancer
Cancer Vaccine Strategies
RNA-Loaded Dendritic Cells Cancer Vaccine:
Liposomal Vaccine:
Vaccine Targeting Pregnancy Hormone:
Viral Vector Vaccine:
Listeria-Based Vaccine:
Telomerase Targeting Vaccine:
Cancer Vaccine Makes Debut in the US, Finally
Approved Therapeutic Cancer Vaccines Worldwide
Cancer Vaccine Pipeline Shows Significant Promise
World Cancer Vaccine Pipeline as of 2011
Long-Drawn Journey to Success Offers New Lessons for Drug Makers

7. HORMONE THERAPY

Current and Future Analysis
Hormonal Therapy – An Overview
Hormonal Therapy Strategies
Hormone Synthesis Inhibitors
Aromatase Inhibitors
GnRH Analogs
Hormone Receptor Antagonists
Selective Estrogen Receptor Modulators (SERMs)
Antiandrogens
Hormone Supplementation
Progestagens and Androgens
Estrogens
Somatostatin Analogs
Shifting Therapeutic Preferences

Table 10. Global Market for Antihormonal Therapy (2005 and 2014): Percentage Breakdown of Revenues by Drug Class - LHRH Analogs, Aromatase Inhibitors, Anti-androgens, Anti-estrogens, and Other Hormone Antagonists (includes corresponding Graph/Chart)

Drug Classes in Hormone Therapy
Drugs Used in Hormone Therapy and Their Uses
Side-Effects Associated with the Use of Various Drugs in Hormone Therapy

8. CHEMOTHERAPY

Current and Future Analysis
Chemotherapy – An Overview
The Chemotherapy Market Space – An Overview
Chemotherapy Market Cluttered with Numerous Players
Chemotherapy Drugs Require Careful Handling
Types of Chemotherapy
Adjuvant Chemotherapy
Combined Modality Chemotherapy
Neoadjuvant Chemotherapy
Palliative Chemotherapy
Chemotherapy Drug Classes
Nucleoside Analogues
Alkylating Agents
Antimetabolites
Nitrosoureas
Steroid hormones
Platinum Containing Compounds
Folate antagonists
Microtubule-targeting agents
Topoisomerase inhibitors
Risks Associated with Chemotherapy
When Chemotherapy Fails…

9. AN OVERVIEW OF CANCERS

Cancer: A Major Health Crisis in the Modern World

Table 11. Cancer Causes in Developed and Developing Countries (2010): Percentage Breakdown by Risk Factors – Diet or Nutrition, Infections, Tobacco, and Other Factors (includes corresponding Graph/Chart)

Types of Cancers
Prostate Cancer
Select FDA-Approved Prostate Cancer Drugs
Select Prostate Cancer Agents in Mid- & Late-Stage Clinical Development

Table 12. Revenues of Select Leading Prostate Cancer Drugs: 2006-2010 (includes corresponding Graph/Chart)

Breast Cancer
Select FDA Approved Breast Cancer Drugs

Table 13. Breast Cancer Drug Pipeline: Number of Drugs by Development Stage as of 2010 (includes corresponding Graph/Chart)

Cervical Cancer
Colorectal Cancer
Select FDA-Approved Colorectal Cancer Drugs

Table 14. Colorectal Cancer Drug Pipeline: Number of Drugs by Development Stage as of 2010 (includes corresponding Graph/Chart)

Lung Cancer
Select FDA-Approved Non-Small Cell Lung Cancer Drugs

Table 15. Lung Cancer Drug Pipeline: Number of Drugs by Development Stage as of 2010 (includes corresponding Graph/Chart)

Renal Cancer
Select FDA-Approved Renal Cell Carcinoma Drugs
Skin Cancer

Table 16. Skin Cancer/Melanoma Drug Pipeline: Number of Drugs by Development Stage as of 2010 (includes corresponding Graph/Chart)

Pancreatic Cancer

Table 17. Pancreatic Cancer Drug Pipeline: Number of Drugs by Development Stage as of 2010 (includes corresponding Graph/Chart)

Non-Hodgkin’s Lymphoma
Leukemia
Bladder Cancer

Table 18. Bladder Cancer Drug Pipeline: Number of Drugs by Development Stage as of 2010 (includes corresponding Graph/Chart)

Endometrial Cancer

10. WORLD CANCER STATISTICS

Cancer Incidence – Statistics on New Cases

Table 19. Global Cancer Incidence by Region: 2009 (includes corresponding Graph/Chart)
Table 20. Global Cancer Incidence by Income Group: 2009 (includes corresponding Graph/Chart)
Table 21. Cancer Incidence in Upper Middle Income Countries by Site: 2009 (includes corresponding Graph/Chart)
Table 22. Cancer Incidence in Lower Middle Income Countries by Site: 2009 (includes corresponding Graph/Chart)
Table 23. Cancer Incidence in High Income Countries by Site: 2009 (includes corresponding Graph/Chart)

11. DRUG APPROVALS AND CLINICAL TRIALS

Merck Receives Approval for EMEND® IV in Canada
Sun Pharma Receives FDA Approval for Docefrez
Amgen Secures FDA Approval for Denosumab
Eisai Receives FDA Approval for Halaven
Dendreon Corporation Secures FDA Approval for Provenge
GlaxoSmithKline Secures Accelerated Approval from FDA for TYKERB
Roche Receives European Commission Approval for Herceptin in Metastatic Gastric Cancer Treatment
Gloucester Pharmaceuticals Receives FDA Approval for Istodax
YM BioSciences Gains Marketing Approval for Nimotuzumab in Mexico
Bristol-Myers and ImClone Receives FDA Approval for Erbitux Labeling Revisions
Abraxis Receives Approval for Abraxane in Quebec, Canada
Genentech Receives FDA Approval for Avastin
ABRAXANE Gains Marketing Approval in Korea, Australia and Other Countries
GlaxoSmithKline's Cervarix Finds Place in UK National Immunization Programme
Biogen Idec and Elan Commence Clinical Trial of TYSABRI
Calistoga Pharmaceuticals Starts Phase I Clinical Trial of CAL-101
Progen Pharmaceuticals Continues Phase 1 Development of PG-11047
GlaxoSmithKline Receives Conditional EU Approval for Marketing Lapatinib
Roche’s Xeloda Gains EU Approval for Use in Colorectal Cancer Treatment
Genentech Secures FDA Approval for Avastin
EU Approves Four Biosimilar Versions of Neupogen
Russia Approves Oncophage for Kidney Cancer Treatment
Eisai to Start Clinical Testing of MORAb-028
Threshold Pharmaceuticals Starts Phase I/II Clinical Trials of TH-302
AVEO Commences Phase 1b Clinical Study of AV-951 and FOLFOX6
GSK’s Tykerb Receives USFDA Approval
Seattle Genetics Initiates Phase 1b Clinical Trials of SGN-40 with Gemzar and Rituxan
S*Bio Initiates Phase I Clinical Trials of SB1518
Merck Serono Initiates Phase III Trials of Cladribine
BioCurex Receives Patent for RECAF Technology Applications
Chidamide/HBI-8000 Completes Phase I Clinical Trials in China
AVEO Initiates Phase I Trials of AV 299
Exelixis Completes Phase I Trials of XL765
Infinity Pharmaceuticals Starts Phase I Clinical Trial of IPI-926
Cell Genesys Terminates its VITAL-1 Phase 3 Trial of GVAX
GTx Completes Phase II Clinical Trials of Ostarine
Imclone Awaits Approval for Erbitux from US Medicine Regulator
Kuhnil and Daiichi Sankyo Initiate Phase II Clinical Trial of Nimotuzumab
Peplin Starts Phase III Clinical Trials of PEP005 Gel
ERBITUX Receives Marketing Approval in Japan
Progenics Starts Phase I Clinical Study of PSMA ADC
FDA Awards Orphan Drug Designation for the Use of Stem Cell Technology in Bone Marrow Transplantations
Roche, OSI and Chugai Receive Approval for Tarceva in Japan
Eisai Receives FDA Approval for ONTAK®
Genmab Terminates the Development of HuMax-CD4
Teva Pharmaceutical Acquires EU Authorization to Market Neutropenia Drug
Novartis’ Everolimus Awaits Approvals from US FDA, Swissmedic, and EMEA
Abraxis BioScience, AstraZeneca, and NCCN to Conduct Anti-cancer Drug Studies
Sanofi-Aventis Receives Japanese Approval for Taxotere® Injection
Roche’s Avastin Bags European Approval for Renal Cancer Treatment
Roche Announces European Approval of Herceptin
GSK’s Hycamtin Obtains FDA Approval
Avastin Receives European Approval for Breast Cancer Treatment
Roche’s Tarceva Obtains European Approval
Roche’s NeoRecormon Gains European Approval
Northwest Biotherapeutics’ DCVax-Brain Gains Swiss Approval
Alfacell’s ONCONASE Receives Orphan Drug Designation from US
Cougar Biotechnology Commences Phase II Trial of CB7630
Lorus Therapeutics Receives Orphan Drug Designation for its LOR-2040
Merck Serono Receives EU Approval for mCRC Treatment With Erbitux
MGI PHARMA and HELSINN Receive FDA Approval For Aloxi
FDA Grants Approval for Sutent, a Kidney and Gastrointestinal Cancer Drug
Wyeth Pharmaceuticals’ TORISEL Receives FDA Approval
Dabur Pharma Acquires FDA Approval for Paclitaxel Injection
EUSA’s CAPHOSOL Finds Application in Treating Oral Mucositis
European Commission Approves Amgen’s Vectibix for Metastatic Colorectal Cancer
GPC Biotech Starts Phase 2 Trials of Satraplatin plus with Tarceva
FDA Approves Vectibix as Treatment for Metastatic Colorectal Cancer
FDA Approves IND Indication for CYT-500 of Cytogen
FDA Clears Rituxan for New Indications
Epeius Receives BFAD Approval for Expanded Access Program for Rexin- G
BioMedicines Initiates Phase 1b Study of Biomed 101
Avastin Obtains FDA Approval for Treating Recurrent Colorectal Cancer
Genentech’s Herceptin Gains FDA Nod for Treating Early stage Cancer after Surgery
Epeius Starts Phase I and II Trials of the New Tri-Rex Vaccination Protocol
Sonus Begins Phase 1 Clinical Trial of TOCOSOL® Camptothecin
Dynavax Begins Phase 1 Clinical Trial of TLR9 agonist Combined with Chemotherapy Regimen
Morphotek’s MORAb-009 Receives Orphan Drug Designation
Morphotek’s MORAb-003 Receives Orphan Drug Status from the US FDA
Morphotek Grants FDA Approval of the IND for MORAb-009
MannKind Receives IND Clearance for MKC1106-PP Immunotherapy
Pharmexa Initiates Phase II trials of GV 1001
Wyeth Pharmaceuticals Declares Discontinuation of Phase III Clinical Trials for Temsirolimus
OXiGENE Announces Clinical Trials of CA4P
Glaxo SmithKline’s Hycamtin Gains FDA Approval for Treating Cervical Cancer
Cell Genesys Announces the Initiation of Amplified Phase I Trial of CG0070
Genentech’s Avastin Receives FDA Approval for Lung Cancer Treatment
Vorinostat Acquires FDA Approval for Skin Cancer Treatment
Callisto Launches the First Clinical Trial of Landmark Discovery, L-Annamycin for ALL
Shanghai Sunway Biotech’s H101 Receives Marketing Approval in China
Northwest Biotherapeutics Gains Patent for CXCR4
Biocon’s Cancer Drug Initiates Phase II Trials

12. NEW DRUG DEVELOPMENTS AND LAUNCHES

Dr Reddy's Laboratories Introduces Peg-Grafeel Injection in India
Sanofi-Aventis Introduces Jevtana (cabazitaxel) Injection in the US
Natco Pharma Introduces Anastrazole for Breast Cancer in US
Dr Reddy's Laboratories Introduces Anastrazole Tablets in US
Zynx Health Introduces Zynx OncologyCare
Ferring Pharmaceuticals Introduces FIRMAGON® in Europe
GSK Launches Cervarix in Singapore
Abeome Launches New Stem Cell Monoclonal Antibody
Dabur Pharma Launches a New Drug Delivery System, Nanoxel
Epeius Biotechnologies Develops New Targeted Anti-Cancer Drugs
Monash University Scientists Develop siRNA for Cancer Treatment
Cytogen Introduces SOLTAMOX™, the First Hormonal Breast Cancer Therapy

13. RECENT INDUSTRY ACTIVITY

BioLineRx Acquires License Rights of BL-7030 from Algen
Glenmark Establishes New Manufacturing Plant in Argentina
Centella Therapeutics Signs Licensing Agreement with Auckland UniServices
Cephalon Enters a Definitive Merger Agreement with Gemin X
IRX Therapeutics Enters a New Research Collaboration
RXi Pharmaceuticals Acquires Apthera
Gilead Sciences to Enter into Collaboration with Yale School of Medicine for Cancer Therapies
Sage Bionetworks Forms Alliance with AstraZeneca
Amgen Acquires BioVex Group
AREVA Inks Cooperative Research Agreement with INSERM
Dendreon Secures FDA Approval for New Jersey Manufacturing Facility
Celgene Acquires Abraxis BioScience
HUYA Partners with Quintiles to Co-Develop HBI-8000 Cancer drug (US/China)
China PharmaHub Signs Agreement with Global Player in Precision Glass Technology
Immunotope Partners with Midatech Group to Form Syntara
ChromoCure Acquires GRG
Qatar National Cancer Society and SAH Global Sign MoU
Neogenix Gains FDA Orphan Drug Designation for Ensituximab
ImmunoGen Gains Orphan Drug Status for Lorvotuzumab Mertansine
Syngene International Enters Into Agreement with Endo Pharmaceuticals
Immunovaccine and Oncothyreon Ink Research Agreement
OncoGenex Inks Licensing Agreement with Teva Pharmaceutical
NanoCarrier Enter into Comprehensive Joint Research Agreement with MEDINET
VaxOnco Acquires Intellectual Property Rights for Onyvax-P
Novation Pharmaceuticals and Cancer Therapeutics Enter into Collaboration
Cancer Therapeutics Signs Letter of Intent with NanoTherapies
sanofi-aventis Acquires BiPar Sciences
IBt Bebig, Rusnanotech and Santis Form Joint Venture for Cancer Treatment
Roche Acquires Genentech
AstraZeneca Enters into Collaboration with Merck
Cytopia Merges with YM BioSciences
Aveo Pharmaceuticals and Biogen Idec Sign Definitive Agreement
Opsona Therapeutics Inks Research and Collaboration Agreement with CSL
Micromet Signs Agreement with Lonza
Clavis Pharma Enters Into Agreement with Clovis Oncology
Abraxis Takes Over Platco and Shimoda
WEHI Collaborates with Abbott and Genentech
Novartis Inks a Production Deal with Lonza
Roche Takes Over UK-Based Biotech Company, Piramed
Pfizer Acquires Encysive
Eden Biodesign Inks a Marketing Services Deal with Human Genome Sciences
FivePrime Join Hands with Pfizer for Cancer and Diabetes Research
Sanofi-Aventis and Dyax Ink Two Antibody Pacts
Pfizer and AVANT Ink a Global Licensing Agreement for CDX-110
Takeda Inks an Exclusive Partnership Agreement with Amgen
Genentech and Roche Ink a Licensing Agreement with Glycart
Bristol-Myers Squibb Acquires Kosan Biosciences
Nabi Biopharmaceuticals Collaborates with NIAID
Pfizer to Acquire Serenex
Morphotek Signs an Agreement with Pivotal BioSciences
GE Healthcare Inks a Three-Year Agreement with Eli Lilly
ArQule Signs Two Agreements with Daiichi Sankyo
Circadian Completely Acquires Vegenics Limited
Lpath Inks an Accord with Merck Serono
Topex Expands its Distribution Deal with Therapy Remarketing
Unibioscreen Inks a Partnership Agreement with Drais Pharmaceuticals
Avant Immunotherapeutics Becomes Celldex Therapeutics
Abraxis Enters into Definitive License Agreements with ProMetic Life Sciences
Biovest International to Receive US$1. 6 Million Funding for Biomedical Research
Access Completes the Acquisition of Somanta
Clinical Data Inks an Agreement to Take Over Avalon Pharmaceuticals
EUSA Pharma Acquires Cytogen Corporation
Oncologic Merges with Triton BioSystems
Eli Lilly Takes Over ImClone Systems
CEL-SCI Establishes a New Manufacturing Unit
ZaBeCor Establishes Biothorpe Pharmaceuticals, a New Subsidiary
Takara Bio Signs a Research Agreement with a Chinese University
Shanghai Roche Expands its MabThera Marketing Activities
Merck Completes the Acquisition of Majority Stake in Serono
Merck Enters into Licensing and Collaboration Agreement With Idera
Sanofi-Aventis Inks a Global Licensing Deal with Oxford BioMedica
WEHI to Collaborate with Genentech and Roche
AstraZeneca Acquires MedImmune
Antisoma Enters into a Global Accord with Novartis
Sanofi-Aventis and Astellas Pharma to Restructure their JV Operations in Japan
Biomira Amends its Agreements with Merck
AstraZeneca Takes Over Canadian Biologics Plant
Pfizer Acquires Coley Pharmaceutical Group
Abraxis Takes Over Watson’s Manufacturing Facility
Abraxis Takes Over Pfizer’s Cruce Davila Manufacturing Facility
Bristol-Myers Squibb Takes Over Adnexus Therapeutics
Merck Partners with a Florida-based Research Center
Organon Partners with Medarex
Genzyme Acquires Bioenvision
Genentech Inks a Deal with Seattle Genetics
TopoTarget Takes Over Apoxis
Roche Acquires CuraGen’s Subsidiary
GPC Biotech Inks an Agreement with Yakult
MediGene Acquires Avidex
Sanofi-Aventis Inks an Agreement with Taiho
Biogen Inks Merger Agreement with Conforma
Roche Signs a Merger Agreement with Ventana
Roche Takes Over THP to Enhance Its Therapeutic Antibody Profile
ImClone Systems and Merck Revise ERBITUX Agreement
GSK Invests €500 Million in France
Amgen Takes Over Avidia
Moores Cancer Center Collaborates with Medarex
ADITUS Medical Forms an Alliance with IGEA
Callisto Opens Site For Phase–II Clinical Trials of Atiprimod
XOMA Inks an Agreement with Attenuon
AstraZeneca Joins Schering to Develop a Novel Breast Cancer Drug
Nventa to Procure Hiltonol from Oncovir Incorporated
MaxCyte and Medinet Sign an Agreement for Immuno- Cell Therapy
Receptor Acquires Cancer Vaccine ‘G17DT’ from Aphton
Enzon Collaborates with Santaris for Joint Development of Novel RNA Antagonists
Epeius Receives Funding from Lazarex for Rexin-G™ Trials
Callisto Inks a Deal with M. D. Anderson Cancer Center
AstraZeneca Inks an Agreement with Abraxis BioScience
diaDexus and BVF Establish CFD Therapeutics
Merck Acquires US Rights for Liposome Vaccine
Genentech Enters Into Alliance with Inotek
AstraZeneca Takes Over KuDOS Pharmaceuticals
Genzyme Acquires AnorMED
Genentech Collaborates with Accelerate Brain Cancer Cure
Sonus and Schering Enter into a Global Licensing Agreement
Abgenix Inks Merger Agreement with Amgen
AstraZeneca and Astex Enter into an Alliance
Pfizer Inks Global License Pact with Coley Pharmaceutical Group
Genzyme Takes Over ILEX Oncology
Genentech and CGI Enter into an Exclusive Agreement

14. FOCUS ON SELECT PLAYERS

Amgen, Inc. (USA)
Amgen’s Oncology Pipeline As of 2011
AstraZeneca PLC (UK)
AstraZeneca’s Cancer Drugs Under Pipeline as of 2011
Bayer Schering Pharma (Germany)
Bayer’s Oncology Pipeline (As of 2011)
Biogen Idec Inc (USA)
Bristol-Myers Squibb Company (USA)
Celgene Corporation (USA)
Celgene’s Oncology Drug Pipeline (As of 2011)
Cell Therapeutics, Inc. (USA)
Cell Therapeutics’ Oncology Pipeline (As of 2011)
Cephalon, Inc. (USA)
Cephalon’s Oncology Pipeline (As of 2011)
Chugai Pharmaceutical Co. , Ltd. (Japan)
Chugai’s Oncology Drug Pipeline (As of 2011)
Eli Lilly and Company (USA)
Lilly’s Oncology Drug Pipeline as of 2011
Imclone Systems, Inc (USA)
F. Hoffmann-La Roche Ltd (Switzerland)
Select Mid- and Late- Stage Compounds in Roche’s Oncology Pipeline
Genentech, Inc. (USA)
Genzyme (USA)
Genzymes’ Oncology Drug Pipeline as of 2011
GlaxoSmithKline (UK)
GlaxoSmithKline’s Oncology Pipeline (As of 2011)
Janssen Biotech, Inc (USA)
Merck KGaA (Germany)
Merck Serono’s Oncology Pipeline (As of 2011)
Novartis AG (Switzerland)
Novartis’ Oncology Drug Pipeline (As of 2011)
OSI Pharmaceuticals, Inc. (USA)
OSI Pharmaceuticals’ Oncology Pipeline Status (As of 2011)
Pfizer (USA)
Pfizer’s Oncology Drug Pipeline (As of 2011)
Sanofi-Aventis (France)
Oncology Drug Pipeline of sanofi-aventis as of 2011
Seattle Genetics, Inc. (USA)
Seattle’s Cancer Therapy Pipeline as of 2011
Takeda Pharmaceutical Company Limited (Japan)
Takeda’s Oncology Pipeline (As of 2011)

15. GLOBAL MARKET PERSPECTIVE

Table 24. Global Recent Past, Current & Future Analysis for Cancer Therapies by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 25. Global Historic Review for Cancer Therapies by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 26. Global 15-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

Analytics by Segment

Table 27. Global Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 28. Global Historic Review for Immunotherapy by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 29. Global 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
Table 30. Global Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 31. Global Historic Review for Targeted Therapy by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 32. Global 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
Table 33. Global Recent Past, Current & Future Analysis for Hormone Therapy by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 34. Global Historic Review for Hormone Therapy by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 35. Global 15-Year Perspective for Hormone Therapy by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)
Table 36. Global Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 37. Global Historic Review for Chemotherapy by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 38. Global 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

16. THE UNITED STATES

A. Market Analysis
Current and Future Analysis

Table 39. Sales of Select Leading Cancer Drugs in the US (2009 & 2010) (includes corresponding Graph/Chart)

Recession Hits the Pharma Market, Oncology Area too Succumbs
Medicare Restructures its Coverage for Chemotherapy
Personalized Care for Cancer Treatment in US
Drugs in Development in the US – A Recent Past Scenario
Chemotherapy Drugs Undergoing Trials for Breast Cancer Treatment in United States (as of 2007)
Hormonal Therapy Drugs Undergoing Trials for Breast Cancer Treatment in United States (as of 2007)
Targeted Therapy Drugs Undergoing Trials for Breast Cancer Treatment in United States (as of 2007)
Statistical Findings

Table 40. US Market for Hospital Cancer Therapies (2004 and 2010): Percentage Breakdown of Revenues by Treatment Type – Surgery, Chemotherapy Drugs, Radiation Therapy, Biotechnology-Based Drugs, and Others (includes corresponding Graph/Chart)
Table 41. US Demand for Chemotherapy Drugs (2004 and 2010): Percentage Breakdown of Revenues by Drug Class - Alkylating Agents & Related, Antimetabolites & Related, Mitotic Inhibitors, and Others (includes corresponding Graph/Chart)
Table 42. US Market for Multiple Myeloma Therapeutics (2009): Percentage Breakdown of Revenues by Company - Celgene Corporation, Millennium Pharmaceuticals and Others (includes corresponding Graph/Chart)
Table 43. US Market for Breast Cancer Therapeutics (2010): Percentage Breakdown of Revenues by Segment: Targeted Therapeutics, Cytotoxic Therapeutics, and Hormonal Therapeutics, and (includes corresponding Graph/Chart)

US Cancer Statistics

Table 44. New Cancer Cases in the US by Affected Site: 2009 (includes corresponding Graph/Chart)
Table 45. New Cancer Cases in Males in US by Leading Site: 2009 (includes corresponding Graph/Chart)
Table 46. New Cancer Cases in Females in US by Leading Site: 2009 (includes corresponding Graph/Chart)

Cancer Mortality Statistics

Table 47. Cancer Related Deaths in the US By Affected Site: 2009 (includes corresponding Graph/Chart)
Table 48. Cancer Related Deaths in Males in US by Leading Site: 2009 (includes corresponding Graph/Chart)
Table 49. Cancer Related Deaths in Females in US by Leading Site: 2009 (includes corresponding Graph/Chart)

New Drug Approvals
New Drug Launches
Strategic Corporate Developments
Focus on Select Major Players
B. Market Analytics

Table 50. The US Recent Past, Current & Future Analysis for Cancer Therapies by Segment – Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 51. The US Historic Review for Cancer Therapies by Segment – Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 52. The US 15-Year Perspective for Cancer Therapies by Segment - Percentage Breakdown of Dollar Sales for Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

17. JAPAN

A. Market Analysis
Current and Future Analysis
Focus on Select Major Players
B. Market Analytics

Table 53. Japanese Recent Past, Current & Future Analysis for Cancer Therapies by Segment – Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 54. Japanese Historic Review for Cancer Therapies by Segment – Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 55. Japanese 15-Year Perspective for Cancer Therapies by Segment - Percentage Breakdown of Dollar Sales for Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

18. EUROPE

A. Market Analysis
Current and Future Analysis
Regional Perspective
Advancements in Breast Cancer Treatment in Europe
New Formulations that are Under Clinical Trials
Drugs Undergoing Trials for Bladder Cancer Treatment in Europe As of 2006
European Cancer Statistics

Table 56. Cancer Incidence in Europe by Site (2009) (includes corresponding Graph/Chart)

New Drug Approval
New Drug Launch
Strategic Corporate Developments
Focus on Select Major Players
B. Market Analytics

Table 57. European Recent Past, Current & Future Analysis for Cancer Therapies by Segment – Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 58. European Historic Review for Cancer Therapies by Segment – Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 59. European 15-Year Perspective for Cancer Therapies by Segment - Percentage Breakdown of Dollar Sales for Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

19. REST OF WORLD

A. Market Analysis
Current and Future Analysis
Regional Market Overview
Canada

Table 60. Estimated New Cancer Cases by Type/ Site Among Canadian Men: 2010 (includes corresponding Graph/Chart)
Table 61. Estimated New Cancer Cases by Type/Site Among Canadian Women: 2010 (includes corresponding Graph/Chart)
Table 62. Estimated Cancer Deaths by Type/Site Among Canadian Men: 2010 (includes corresponding Graph/Chart)
Table 63. Estimated Cancer Deaths by Type/Site Among Canadian Women: 2010 (includes corresponding Graph/Chart)

Asia
Cancer Statistics in Asia-Pacific

Table 64. Cancer Incidence in Asia-Oceania by Site: 2009 (includes corresponding Graph/Chart)

Australia
India
Korea
Malaysia
Latin America
Brazil
Mexico
Argentina
New Drug Approvals
New Drug Launches
Strategic Corporate Developments
B. Market Analytics

Table 65. Rest of World Recent Past, Current & Future Analysis for Cancer Therapies by Segment – Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 66. Rest of World Historic Review for Cancer Therapies by Segment – Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 67. Rest of World 15-Year Perspective for Cancer Therapies by Segment - Percentage Breakdown of Dollar Sales for Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE

Total Companies Profiled: 152 (including Divisions/Subsidiaries - 168)
Region/CountryPlayers
The United States96
Canada
Japan
Europe
France
Germany
The United Kingdom
Spain
Rest of Europe
Asia-Pacific (Excluding Japan)
Middle-East
Skip to top


Ask Your Question

Cancer Therapies: Market Research Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: